IMCR vs PATH · rev $310.2M vs P/E 19, rev $1.61B
Immunocore Holdings Ltd (IMCR) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Immunocore Holdings Ltd (IMCR) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IMCR revenue for 2024-12-31 was $310.2M. Net income was -$51.1M. Revenue was up 24.4% from 2023-12-31 to 2024-12-31. IMCR currently screens at market cap $1.45B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IMCR currently screens at market cap $1.45B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IMCR and PATH stock pages for the full models.
Not investment advice.